Transcatheter Pulmonary Valve Implantation With the Alterra Adaptive Prestent and SAPIEN 3 Transcatheter Heart Valve: 3-Year Pooled Outcomes of the ALTERRA Trials
- 1 April 2026
- journal article
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (4) , e015873
Abstract
BACKGROUND: The Alterra Adaptive Prestent provides a landing zone for implantation of the 29 mm SAPIEN 3 transcatheter heart valve (THV) in patients with a dysfunctional right ventricular outflow tract (RVOT) to treat pulmonary regurgitation (PR). Here, we report 3-year outcomes from a pooled analysis of patients who underwent Alterra/SAPIEN 3 THV implantation enrolled in the ALTERRA pivotal trial, Continued Access Protocol, and Pulmonic Delivery System Registry. METHODS: This multicenter, prospective trial enrolled patients with moderate or greater PR and RVOT/pulmonary valve anatomy suitable for implantation. The nonhierarchical composite end point of THV dysfunction was examined at 6 months: RVOT/pulmonary valve reintervention, moderate or greater PR, and mean RVOT/pulmonary valve gradient ≥35 mm Hg. Individual components of the composite, as well as additional clinical and echocardiographic outcomes were examined up to 3 years. RESULTS: The Alterra/SAPIEN 3 THV system was implanted in 118 patients at 14 sites. At 6 months, THV dysfunction was 3.5% (4/113). At 3 years, 97.3% of patients in the valve implant population had freedom from reintervention, 100% of patients had a mean RVOT/pulmonary valve gradients <35 mm Hg, and 93.3% of patients had mild or lesser total PR. The Kaplan-Meier estimate of all-cause mortality was 3.5% at 3 years. There were no cases of coronary artery compression, hemopericardium, or endocarditis. CONCLUSIONS: This analysis reports the longest follow-up in the largest cohort of patients from the ALTERRA trials. The Alterra Adaptive Prestent with the SAPIEN 3 THV system has shown excellent procedural outcomes and is effective in reducing PR at 3-year follow-up. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03130777.Keywords
This publication has 23 references indexed in Scilit:
- Acute Left Main Coronary Artery Compression After Harmony‐TPV ImplantationCatheterization and Cardiovascular Interventions, 2025
- Extravascular protrusion of the Alterra adaptive prestent identified on surveillance computed tomography imagingCatheterization and Cardiovascular Interventions, 2024
- The adaptability of the Pulsta valve to the diverse main pulmonary artery shape of native right ventricular outflow tract diseaseCatheterization and Cardiovascular Interventions, 2024
- Five‐year follow‐up after percutaneous pulmonary valve implantation using the Venus P‐valve system for patients with pulmonary regurgitation and an enlarged native right ventricular outflow tractCatheterization and Cardiovascular Interventions, 2023
- Valve Academic Research Consortium 3: Updated Endpoint Definitions for Aortic Valve Clinical ResearchJACC, 2021
- Transcatheter Pulmonary Valve Replacement With the Sapien ProsthesisJACC, 2020
- First human implant of the Alterra Adaptive PrestentTM: A new self‐expanding device designed to remodel the right ventricular outflow tractCatheterization and Cardiovascular Interventions, 2018
- Hybrid pulmonary artery plication followed by transcatheter pulmonary valve replacement: Comparison with surgical PVRCatheterization and Cardiovascular Interventions, 2016
- Development of a novel hybrid strategy for transcatheter pulmonary valve placement in patients following transannular patch repair of tetralogy of fallotCatheterization and Cardiovascular Interventions, 2015
- Results of transcatheter pulmonary valvulation in native or patched right ventricular outflow tractsArchives of Cardiovascular Diseases, 2014